Best Life Sciences Tech Companies in San Diego, United States
The 84 best Life Sciences Tech companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Human Longevity.
Ranked: Best Life Sciences Tech companies in San Diego
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Human Longevity Provider of precision medicine, preventative health assessments, and longevity care | $409M | 22 mo ago | 85 | 2013 | J Venter Co-Founder & CEO | Series B | 8 patents Patents concentrated in computing, sensing & instrumentation | 1 launch · 1 partnership |
| 2 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer | $206M | 2 mo ago | 50 | 2019 | Fred Manby Co-Founder & CTO | Series C | — | — |
| 3 | Expansion Therapeutics Provider of a software system for the development of drugs | $140M | 56 mo ago | 20 | 2016 | Matthew Disney Co-Founder | Series B | — | — |
| 4 | Belharra Provider of photoaffinity-based chemoproteomics platform for drug discovery | $50M | 41 mo ago | 56 | 2021 | Jeff Jonker CEO | Series A | — | — |
| 5 | 1859 Provider of DNA encoded libraries for drug discovery and development | $50M | 55 mo ago | 73 | 2019 | Devon Cayer Co-Founder & CEO | Deadpooled | 30 patents High-throughput microfluidic bioassay platforms for drug and biomolecule screening | — |
| 6 | Creyon Bio Provider of drug design and oligonucleotide-based drug development platform | $40M | 51 mo ago | 38 | 2019 | Swagatam Mukhopadhyay Chief Scientific Officer & Cofounder & Board Member | Series A | — | — |
| 7 | GeneFormatics Tools for protein structure predictions | $40M | 296 mo ago | — | 1998 | David Muth CEO | Series C | — | — |
| 8 | Faro Health Provider of cloud-based clinical trials management tool for a healthcare organization | $38M | 40 mo ago | 20 | 2019 | Scott Chetham Co-Founder & CEO | Series B | — | 1 job opening |
| 9 | Function Oncology Developer of therapeutics to treat cancer | $28M | 38 mo ago | 16 | 2018 | Christian Schmedt Co-Founder | Series A | 9 patents Functional genomic profiling of cancers using CRISPR-based personalized screening | — |
| 10 | Illumina Developer of technologies for analysis of genetic variation and function | $28M | 77 mo ago | 5,548 5,548 → 9,678 (+74%) | 1993 | Mark Chee Co-Founder | Public | 10,583 patents High-throughput DNA sequencing hardware, reagents, and AI-driven base‑calling technologies | — |
| 11 | VivoSense Wearable sensor CRO providing precision insights for clinical trials | $27M | 51 mo ago | 49 | 2010 | Lance Myers Co-Founder | Series A | — | — |
| 12 | Condor Software-based financial management platform for clinical industries | $24M | 3 mo ago | 8 | 2003 | John Sammataro Co-Founder | Series A | — | — |
| 13 | Model Medicines Developer of AI-based drug discovery platform | $20M | 7 mo ago | 26 | 2019 | Daniel Haders II Chief Executive Officer | Series A | 7 patents Antiviral therapeutics targeting DNA/RNA viruses, including SARS‑CoV‑2, using pipendoxifene. | — |
| 14 | Sinopia Biosciences Data-driven drug discovery using multi-omics, AI, and disease models | $19M | 3 mo ago | 4 | 2014 | — | Funding Raised | — | — |
| 15 | Symyx Technologies Informatics and automation products for research. | $15M | 212 mo ago | 107 | 1994 | Isy Goldwasser ex-CEO | Public | 372 patents Advanced polymerization catalysts for ultra‑high‑molecular‑weight polyethylene production | — |
| 16 | Aizen Therapeutics Provider of AI-based platfrom for drug development | $13M | 19 mo ago | — | 2022 | Ajay Kshatriya CEO | Series B | — | — |
| 17 | Modulo AI-powered drug development platform to treat neurological conditions | $8M | 19 mo ago | 16 | 2021 | Michael Horowitz Co-Founder & CEO | Series A | — | — |
| 18 | Liquid Grid Social media marketing platform for healthcare organizations | $6M | 121 mo ago | 4 | 2010 | — | Acqui-Hired | — | — |
| 19 | Trio Health Provider of data collection and collaboration platform for tracking patient treatment course | $4M | 138 mo ago | 17 | 2011 | — | Series A | — | — |
| 20 | Epitracker Developer of small molecules for treating aging and associated diseases | $3M | 70 mo ago | 4 | 2007 | — | Funding Raised | 8 patents Therapeutic fatty‑acid analogs for metabolic syndrome, obesity, aging, and mood disorders | — |
| 21 | GeneGo GeneGo provides biology and disease information, analytics, and decision support solutions for pharmaceutical… | $3M | 189 mo ago | 10 | 2000 | — | Acqui-Hired | 2 patents Computational prediction of drug metabolism/toxicity and network-based protein target discovery | — |
| 22 | Molsoft Innovative software and consulting for drug discovery, molecular modeling, and cheminformatics | $2M | 194 mo ago | — | 1994 | — | Funding Raised | — | 2 partnerships |
| 23 | SciCrunch Provider of tools and platforms enhancing research reproducibility and transparency | $2M | 89 mo ago | 6 | 2016 | Maryann Martone Co-Founder | Funding Raised | — | 1 partnership |
| 24 | Snap Bio Provider of AI based cheminformatics solution for drug discovery | $2M | 94 mo ago | 1 | 2017 | Mark Burk President And Ceo | Deadpooled | — | — |
| 25 | ScienceMedia Online learning platform provider for medical professionals | $2M | 76 mo ago | 28 28 → 28 (+0%) | 1994 | — | Series B | 5 patents Document annotation and interactive learning platforms for educational content | 1 launch |
| 26 | BioTuring Provider of software for RNA sequence data analysis | $1M | 103 mo ago | 20 | 2016 | Fred H. Gage Co-Founder & CEO | Seed | — | — |
| 27 | Agena Bioscience Genetic analysis technology company providing rapid and accurate solutions for research | $615K | 101 mo ago | 147 | 2014 | Pete Dansky CEO | Acquired | 17 patents Enhanced MALDI mass spectrometry sample prep and multiplex nucleic acid detection technologies. | — |
| 28 | IntelliGuard RFID solutions for the pharmaceutical and healthcare industries | $355K | 185 mo ago | 51 | 2006 | Shariq Hussain Co-Founder & CTO | Seed | — | 1 partnership |
| 29 | Narwhal Bio Provider of a single-cell multi-omics platform for drug discovery | $350K | 21 mo ago | — | 2021 | Behrad Azimi CEO and Co-Founder | Funding Raised | — | — |
| 30 | Oloren AI Provider of AI-based molecular property prediction platform for drug discovery | $300K | 49 mo ago | 10 | 2021 | — | Deadpooled | — | — |
| 31 | Salgomed Develops platforms of multi-drug therapies and provides information about the clinical efficacy of drug… | $296K | 128 mo ago | 2 | 2009 | Giovanni Paternostro CEO | Seed | 2 patents Synthetic biology control systems and combinatorial kinase inhibitor therapy design | — |
| 32 | Abterra Biosciences Platform for antibody sequencing and analysis | $200K | 15 mo ago | 9 | 2009 | — | Seed | — | 1 launch |
Top 12 Life Sciences Tech companies in San Diego
#1
Series C · San Diego, California · founded 2019 · 50 employees$206.2Mraised▾
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
- Apr 2026Series C$27.8M
- Nov 2025Series C$100M
- Apr 2024Series B$50M
- Oct 2023Series B$103.2M
#2
Funding Raised · San Diego, California · founded 2014 · 4 employees$19.4Mraised▾
Data-driven drug discovery using multi-omics, AI, and disease models. The company is transforming drug discovery by applying high-throughput multi-omics data, AI/machine learning, network analyses, and disease models to identify novel targets and mechanisms. Their LEADS® platform combines high-throughput screening, multi-omics data, AI, and network analyses to accelerate the discovery of first-in-class therapeutics. They focus on areas with high clinical unmet need, including neurology, oncology, and genetic diseases. By leveraging advances in metabolomics technologies and computational data analysis, they study diseases and compounds at an unprecedented level of biomolecular detail. This approach enables superior predictivity and facilitates the development of innovative medicines. The company collaborates with leading groups to explore therapeutic areas, offering a data-driven approach to advance drug discovery efforts.
- Mar 2026Grant (prize money)—
- Dec 2025Grant (prize money)—
- May 2025Grant (prize money)$318.3K
- Sep 2024Grant (prize money)$2.2M
#3
Series A · San Diego, California · founded 2003 · 8 employees$24Mraised▾
Software-based financial management platform for clinical industries. It automates and manages clinical accruals, financial insights, cash planning, accruals, financial planning, analytics, audits, scenario cash planning, and more. It also offers solutions for vendor management, document management, and more.
- Mar 2026Series A$24M
#4
Series A · San Diego, California · founded 2019 · 26 employees$19.8Mraised▾
Developer of AI-based drug discovery platform. The company focuses on therapeutics for gastric disorders, neurological disorders, weight disorders, and infectious diseases. Also, uses the collection of drug development data, a drug and disease agnostic discovery platform along with AI to develop drugs.
- Oct 2025Series A$3.3M
- Sep 2024Series A$14.8M
- Dec 2023Series A$950K
- Apr 2022Series A$489K
#5
Series B · San Diego, California · founded 2013 · 85 employees$408.7Mraised▾
Provider of precision medicine, preventative health assessments, and longevity care. The company offers comprehensive health assessments to detect life-threatening conditions early. It focuses on data-driven, personalized healthcare designed to uncover health risks. The company provides services to help individuals take control of their health.
- Aug 2024Series B$39.8M
- Mar 2023Series B$32M
- Oct 2022Series B$6.9M
- Jul 2019Series B$30M
#6
Series B · San Diego, California · founded 2022$13Mraised▾
Provider of AI-based platfrom for drug development. It utilizes machine learning to design and develop novel peptides for therapeutic applications for various diseases which include oncology, neurology disorder, and genetic disorder.
- Nov 2024Series B$13M
#7
Series A · San Diego, California · founded 2021 · 16 employees$8Mraised▾
AI-powered drug development platform to treat neurological conditions. The company's Neuroimmune Platform leverages emerging technologies and cutting-edge neuroscience to develop therapeutic drugs that effectively target the neuroimmune system.
- Nov 2024Series A$5.8M
- Jun 2023Series A$8M
#8
Series B · San Diego, California · founded 2016 · 20 employees$140.3Mraised▾
Provider of a software system for the development of drugs. The platform is engaged in the development of RNA-based therapeutics for Myotonic Dystrophy by using proprietary technology. The company also has a suite of proprietary validation tools and second-generation chemistries.
- Sep 2021Series B$80M
- Jan 2018Series A$55.3M
- May 2017Series A$5M
#9
Series A · San Diego, California · founded 2021 · 56 employees$50Mraised▾
Provider of photoaffinity-based chemoproteomics platform for drug discovery. It offers an integrated chemoproteomic-based drug discovery engine to explore protein-ligand interactions in the cell. It is developing drugs for oncology, immuno-oncology, autoimmune and neurodegenerative diseases.
- Jan 2023Series A$50M
#10
Series B · San Diego, California · founded 2019 · 20 employees$38.3Mraised▾
Provider of cloud-based clinical trials management tool for a healthcare organization. The company has developed software that assists with clinical trial data collecting and management. It has features for data management, real-time data analysis, automation of workflow, and more.
- Feb 2023Series B$20M
- Jun 2021Series A$15M
#11
Series A · San Diego, California · founded 2018 · 16 employees$28Mraised▾
Developer of therapeutics to treat cancer. The company leverages a CRISPR-enabled platform to understand cancer to develop the next generation of targeted cancer therapies.
- Apr 2023Series A$28M
#12
Seed · San Diego, California · founded 2009 · 9 employees$200Kraised▾
Platform for antibody sequencing and analysis. The platform utilizes next-generation sequencing technology, mass spectrometry and machine learning to map the antibody response for infectious diseases & cancer and helps in the identification of therapeutic antibodies. It also helps in antibody-protein sequence analysis, monoclonal antibody discovery, B-cells sequencing, and many more.
- Mar 2025Grant (prize money)$1.4M
- Jul 2021Grant (prize money)$1.1M
- May 2021Seed$200K
- Mar 2021Grant (prize money)$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 64,926 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 5247→6216.
- Genentech2537
- UNIV California2530
- Regeneron Pharma2289
- Amgen1537
- Monsanto Technology1428
- UNIV Pennsylvania1221
- Pioneer HI BRED INT1066
- Harvard College1044
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.